Biogen stumbles in crucial ALS study

Even though Biogen's drug candidate tofersen has not achieved its primary endpoint goal in an important phase III study of a particular sub-type of ALS, there are enough positive signs for the company to keep investigating next steps for the drug.
Brian Snyder/Reuters/Ritzau Scanpix | Photo: Brian Snyder/Reuters/Ritzau Scanpix
Brian Snyder/Reuters/Ritzau Scanpix | Photo: Brian Snyder/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by catherine brett

US-based biotech company Biogen has not managed to attain its primary endpoint goal in a crucial phase III study of its canditate tofersen, also called BIIB067, as a treatment for a specific type of ALS, SOD1-ALS, the firm reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading